TITLE

Intensive statin therapy in acute coronary syndromes and stable coronary heart disease: a comparative meta-analysis of randomised controlled trials

AUTHOR(S)
Afilalo, Jonathan; Majdan, Agnieska A.; Eisenberg, Mark J.
PUB. DATE
August 2007
SOURCE
Heart;Aug2007, Vol. 93 Issue 8, p914
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
Background: Intensive statin therapy reduces major adverse cardiovascular events (MACE), but the effect on mortality is unclear. Objective: To determine whether intensive statin therapy reduces all-cause mortality compared with moderate statin therapy in patients with recent acute coronary syndromes (ACS) and stable coronary heart disease (CHD). Methods: Medline, Embase, the Cochrane Database, the internet, and conference proceedings from 1966 to 2006 were searched to identify relevant trials. Selection criteria were randomised allocation to intensive statin therapy (atorvastatin 80 mg/day, simvastatin 80 mg/day, or rosuvastatin 20-40 mg/day) versus moderate statin therapy, recent ACS or stable CHD at the time of randomisation, and ⩾6 months of follow-up. Results: Six trials, encompassing 110 271 patient-years, were pooled. In patients with recent ACS, intensive statin therapy reduced all-cause mortality from 4.6% to 3.5% over 2.0 years (OR=0.75, 95% CI 0.61 to 0.93). In patients with stable CHD, intensive statin therapy had no effect on all-cause mortality over 4.7 years (OR = 0.99, 95% CI 0.89 to 1 .11). Overall, intensive statin therapy was associated with a reduction in MACE (OR=0.84, 95% CI 0.77 to 0.91) and admissions to hospital for heart failure (OR=0.72, 95% CI 0.62 to 0.83). Intensive statin therapy was also associated with an increase in hepatic transaminases >3 times normal (OR= 3.73, 95% CI 2.11 to 6.58) and a trend towards increased creatine kinase >10 times normal and/or rhabdomyolysis (OR= 1.96, 95% CI 0.50 to 7.63). Conclusions: Compared with moderate statin therapy, intensive statin therapy reduces all-cause mortality in patients with recent ACS but not in patients with stable CHD.
ACCESSION #
27040534

 

Related Articles

  • Coronary Heart Disease Mortality After 5 Years of Adjuvant Tamoxifen Therapy: Results from a Randomized Trial. Nordenskjöld, Bo; Rosell, Johan; Rutqvist, Lars-Erik; Malmström, Per-Olof; Bergh, Jonas; Bengtsson, Nils-Olof; Hatschek, Thomas; Wallgren, Arne; Carstensen, John // JNCI: Journal of the National Cancer Institute;11/2/2005, Vol. 97 Issue 21, p1609 

    From January 1, 1983, through December 31, 1992, a total of 4610 patients entered a randomized trial that compared mortality among patients receiving 2 years of adjuvant tamoxifen therapy with that in patients receiving 5 years of adjuvant tamoxifen therapy, 4175 of whom were recurrence free...

  • Cardium Shows Female Cardiac Patients it has a Heart. Arroyo, Arnaldo // Equities;Apr2007, Vol. 55 Issue 2, p52 

    The article focuses on the efforts of California-based company Cardium Therapeutics to combat heart disease among women. Christopher J. Reinhard, founder of Cardium, states that the mortality rates for women have flatlined. It says that Generx, lead product of the company, will reach the Phase...

  • Placing COURAGE in Context: Review of the Recent Literature on Managing Stable Coronary Artery Disease. Coylewright, Megan; Blumenthal, Roger S.; Post, Wendy // Mayo Clinic Proceedings;Jul2008, Vol. 83 Issue 7, p799 

    Coronary artery disease (CAD) is the leading cause of death in the United States, but prevention and intervention efforts are lowering mortality. This progress is being undercut by rising rates of obesity and diabetes, and adherence to evidence-based prevention efforts is less than ideal. Many...

  • Almanac 2011: Acute Coronary Syndromes. The National Society Journals Present Selected Research that has Driven Recent Advances in Clinical Cardiology. Knight, Charles; Timmis, Adam D. // Materia Socio Medica;2011, Vol. 23 Issue 3, p161 

    This overview highlights some recent advances in the epidemiology, diagnosis, risk stratification and treatment of acute coronary syndromes. The sheer volume of new studies reflects the robust state of global cardiovascular research but the focus here is on findings that are of most interest to...

  • COURAGE 5 years on: the message grows stronger. Boden, William E. // Heart;Dec2012, Vol. 98 Issue 24, p1757 

    In this article, the author reflects on use of catheter-based technology, percutaneous coronary intervention (PCI) in treatment of patients with coronary artery disease. It has been revealed through clinical trials that PCI does not result in reduction of death or non-fatal myocardial infarction...

  • Treating average cholesterol levels in patients with coronary heart disease. Lindbloom, Erik J. // Journal of Family Practice;Feb1999, Vol. 48 Issue 2, p94 

    The article cites a research study that investigates whether reduction of average cholesterol levels with pravastatin in patients with coronary heart disease (CHD) can reduce mortality and cardiovascular events. This multicenter trial recruited patients aged 31 to 75 years in Australia and New...

  • Prognostic importance of tissue Doppler-derived diastolic function in patients presenting with acute coronary syndrome: a bedside echocardiographic study. Richardson-Lobbedez, Marjorie; Maréchaux, Sylvestre; Bauters, Christophe; Darchis, Julie; Auffray, Jean Luc; Bauchart, Jean Jacques; Aubert, Jean Marc; LeJemtel, Thierry H.; Lesenne, Martine; Van Belle, Eric; Goldstein, Patrick; Asseman, Philippe; Ennezat, Pierre V. // European Journal of Echocardiography;Sep2008, Vol. 9 Issue 5, p594 

    Aims: We sought to evaluate the prognostic value of bedside tissue Doppler derived diastolic function in patients presenting with acute coronary syndrome (ACS) on top of major clinical predictors of mortality and routine laboratory testings.

  • MORTALITY, MORBIDITY AND QUALITY OF LIFE FOLLOWING CARDIAC REH AB I LITATION; RESULTS OF A MULTICENTRE RANDOMISED CONTROLLED TRIAL. West, R. // Journal of Epidemiology & Community Health;Aug2004 Supplement 1, Vol. 58, pA61 

    The article presents a study related to The article presents a study related to mortality, morbidity and quality of life. Evidence for cardiac rehabilitation (CR) following acute myocardial infarction (MI) is based largely on small trials performed before routine use of thrombolysis and...

  • Screening for Coronary Artery Disease in Patients With Diabetes. Bax, Jeroen J.; Young, Lawrence H.; Frye, Robert L.; Bonow, Robert O.; Steinberg, Helmut O.; Barrett, Eugene J. // Diabetes Care;Oct2007, Vol. 30 Issue 10, p2729 

    Coronary artery disease (CAD) accounts for a large fraction of the morbidity, mortality, and cost of diabetes. Recognizing this, nearly 10 years ago the American Diabetes Association published a consensus recommendation that clinicians consider a risk factor-guided screening approach to early...

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics